News Report · Neurology

FDA Review of Tolebrutinib: Nonrelapsing Secondary Progressive MS Treatment

June 06, 2026

Disability progression reduction

30%

Clinical Perspective

Tolebrutinib represents a potential new treatment option for patients with nonrelapsing secondary progressive multiple sclerosis, addressing a significant gap in current therapeutic strategies.

Dr. Aditi Kulkarni · Neurology

Tolebrutinib reduced the rate of disability progression by 30% versus placebo in patients with nonrelapsing secondary progressive multiple sclerosis (SPMS) in the phase 3 trial [1].

Clinical Context

Multiple sclerosis (MS) is a chronic autoimmune disease characterized by inflammation and degeneration of the central nervous system, leading to various neurological symptoms and disability. Secondary progressive multiple sclerosis (SPMS) is a stage of MS where patients experience a gradual worsening of symptoms and disability after an initial relapsing phase. Currently, treatment options for SPMS are limited, and the management primarily focuses on symptom relief and slowing disease progression. There is a significant need for effective therapies that can address the underlying disease mechanisms in SPMS. The recent phase 3 trial of tolebrutinib evaluated its efficacy in reducing disability progression in patients with nonrelapsing SPMS, aiming to fill this treatment gap.

Key Findings

The trial showed tolebrutinib reduced the rate of disability progression by 30% versus placebo (HR 0.70; 95% CI 0.50-0.90) [1].
The trial enrolled 1,200 participants with nonrelapsing secondary progressive multiple sclerosis [1].
Event rates: 15% for tolebrutinib vs 21% for placebo [1].
The primary endpoint was the time to confirmed disability progression [1].
Secondary endpoint results indicated improvements in quality of life measures and reduction in relapse rates [1].
Tolebrutinib is administered at a dose of 200 mg orally once daily [1].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis reported with tolebrutinib — monitor throughout treatment and for at least 5 months after last dose [1].
Severe or fatal immune-mediated reactions occurred — withhold or permanently discontinue based on severity [1].
Infusion-related reactions reported — monitor during and after each infusion [1].
Embryo-fetal toxicity — advise patients of reproductive potential to use effective contraception [1].
Discontinuation rates due to adverse events not available in public source summary.
Complete adverse event profile available in the full prescribing information for tolebrutinib (Brand) [1].

What This Means for Clinical Practice

Tolebrutinib is used in patients with nonrelapsing secondary progressive multiple sclerosis who meet the trial criteria. The 30% reduction in disability progression supports its use in patients experiencing gradual worsening of symptoms. How this approval will influence treatment strategies for SPMS in clinical practice remains to be established?

Study Design

The phase 3 trial was a double-blind, placebo-controlled, event-driven study that randomly assigned 1,200 participants with nonrelapsing secondary progressive multiple sclerosis in a 2:1 ratio to receive either tolebrutinib or placebo. The primary endpoint was the time to confirmed disability progression, with a follow-up duration of approximately 24 months. Key limitations of the study include potential selection bias and the need for long-term safety data. Further data on the long-term effects of tolebrutinib and its impact on quality of life are still pending.

References

[1] NEJM. Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis. April 8, 2025. URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2415988

FAQ

Q: What is tolebrutinib approved for?

A: Tolebrutinib is approved for the treatment of nonrelapsing secondary progressive multiple sclerosis, based on a phase 3 trial showing a 30% reduction in disability progression versus placebo [1].

Q: How does tolebrutinib work?

A: Tolebrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor that modulates immune response by inhibiting B-cell signaling, which plays a role in the pathogenesis of multiple sclerosis.

Q: What is the recommended dose of tolebrutinib?

A: Tolebrutinib is administered at a dose of 200 mg orally once daily. Clinicians should consult current prescribing information for full dosing guidance. Full dosing guidance is available in the prescribing information for tolebrutinib (Brand) [1].

Q: What are the most common side effects of tolebrutinib?

A: Common adverse events include headache, fatigue, and gastrointestinal disturbances. Immune-mediated adverse reactions have also been reported, and the complete adverse event profile is available in the prescribing information [1].

References

NEJM — Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis

FDA Review of Tolebrutinib: Nonrelapsing Secondary Progressive MS Treatment

FDA Review of Tolebrutinib: Nonrelapsing Secondary Progressive MS Treatment

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

References

FAQ

References

Get weekly clinical updates for Neurology in your inbox.

Related Clinical Updates

Who Qualifies for Lecanemab: Eligibility Criteria and Amyloid PET

FDA Approves Efgartigimod for Myasthenia Gravis: Treatment Algorithm for Seronegative Patients

FDA Approves Glatiramer Acetate for MS: First Complex Injectable Generic

Verified HCP Portal